Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0675

+2.7%

Dec 4 12:36 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: boomertree2	5/17/2012 10:52:44 AM
	4 Recommendations Read Replies (2) of 13111

In the last year PVCT management has materially toned down its rhetoric regarding the systemic effect of PV-10, and has been more conservative in promoting its efficacy for locoregional disease control....a claim that is more strongly supported by the FDA trials to date. This more conservative communication is likely due in part to concerns over lawsuits and SEC investigations similar to what Dendreon is dealing with concerning its alleged overstatement of the potential market for Provenge......see article below. SEC Investigating Allegations That Dendreon Misrepresented Provenge's Market. The Wall Street Journal (5/17, Loftus, Subscription Publication) reports that Dendreon Corp. announced yesterday that the US Securities and Exchange Commission is investigating allegations that the company misrepresented information about Provenge, a treatment for prostate cancer, to investors. The story notes that the medication was approved by the FDA in April 2010. The company is said to have given overly optimistic projections about adoption of the medication.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next